Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27139062 | 0.65 | HCAR2 (0.34) | HTT | |
| SCHEMBL10638227 | 0.63 | ALPL (0.34) | HTTALDH1A1TSHR | |
| SCHEMBL6104692 | 0.62 | GABRA1 (0.35) | GABRA1HTR6 | |
| SCHEMBL6104658 | 0.62 | KHK (0.34) | GABRA1HTR6 | |
| SCHEMBL2531574 | 0.60 | GABRA1 (0.43) | GABRA1GABRG2GABRB3 | |
| SCHEMBL20473982 | 0.60 | HTR6 (0.34) | GABRA1HTR6 | |
| SCHEMBL3801386 | 0.59 | PDE10A (0.35) | ALDH1A1LMNA | |
| SCHEMBL23109031 | 0.59 | KMT2A (0.45) | HTR6 | |
| Hydrochloric Acid SCHEMBL20292073 | 0.59 | HTR2C (0.32) | — | |
| SCHEMBL14606593 | 0.59 | MEN1 (0.34) | GABRA1GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003030898-A1 | MODULATORS OF CCR5 CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2003-04-17 | — | — | WO | disclosed |
| US-6511994-B2 | For prophylaxis and therapy of infection by HIV and the treatment of AIDS | MERCK & CO., INC. | 2003-01-28 | — | — | US | disclosed |
| US-20020193407-A1 | Modulators of CCR5 chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193407-A1 | Modulators of CCR5 chemokine receptor activity | CCR5, CXCR3, CXCR1 | GABRA1 1067/4885GABRG2 2217/4885GABRB3 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.